{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:47:06Z","timestamp":1787845626469,"version":"build-2784847793"},"update-to":[{"DOI":"10.1002\/14651858.cd011532","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T00:00:00Z","timestamp":1506470400000}}],"reference-count":77,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011532.pub2","type":"journal-article","created":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T12:46:40Z","timestamp":1506516400000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Terlipressin versus other vasoactive drugs for hepatorenal syndrome"],"prefix":"10.1002","volume":"2017","author":[{"given":"Mads","family":"Israelsen","sequence":"first","affiliation":[{"name":"Odense University Hospital; Department of Gastroenterology and Hepatology; Sdr. Boulevard 29 Odense C Denmark 5000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Krag","sequence":"additional","affiliation":[{"name":"Odense University Hospital; Department of Gastroenterology and Hepatology; Sdr. Boulevard 29 Odense C Denmark 5000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S","family":"Allegretti","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital; Division of Nephrology, Department of Medicine; Boston USA MA 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manol","family":"Jovani","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School; Clinical and Translational Epidemiology Unit, Division of Gastroenterology; 55 Fruit St Boston USA MA 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison H","family":"Goldin","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital; Division of Gastroenterology, Hepatology and Endoscopy; Boston USA MA 02115"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel W","family":"Winter","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital; Division of Gastroenterology, Hepatology and Endoscopy; Boston USA MA 02115"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Lotte","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital Hvidovre; Gastrounit, Medical Division; Kettegaards Alle Hvidovre Denmark 2650"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,9,27]]},"reference":[{"key":"10.1002\/14651858.CD011532.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S0168-8278(06)80204-7","article-title":"Noradrenaline vs terlipressin in hepatorenal syndrome: a prospective, randomized study","volume":"44","author":"Alessandria","year":"2006","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study","volume":"47","author":"Alessandria","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.7123\/01.EJCA.0000431078.82595.1f","article-title":"Norepinephrine versus terlipressin in patients with type 1 hepatorenal syndrome refractory to treatment with octreotide, midodrine, and albumin: a prospective randomized comparative study","volume":"7","author":"Badawy","year":"2013","journal-title":"Egyptian Journal of Cardiothoracic Anesthesia"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial","volume":"63","author":"Cavallin","year":"2016","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0005|cit5","unstructured":"Copaci I Chiriac G Micu L Mindrut E Alternative treatments for hepato-renal syndrome in patients with cirrhosis Falk Symposium 191. Abstract book: Liver Diseases in 2013: Advances in Pathogenesis and Treatment 2013 87"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"S660","DOI":"10.1016\/S0168-8278(16)01240-X","article-title":"Reversal of type 1 hepato-renal syndrome with terlipressin and octreotide","volume":"64","author":"Copaci","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/liv.12179","article-title":"Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study","volume":"33","author":"Ghosh","year":"2013","journal-title":"Liver International"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0008|cit8","first-page":"A76","article-title":"Terlipressin versus noradrenalin in hepatorenal syndrome: a prospective, randomised, unblinded study","volume":"23","author":"Goyal","year":"2008","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0009|cit9","first-page":"30","article-title":"Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1: a prospective, randomized trial","volume":"64","author":"Goyal","year":"2016","journal-title":"Journal of the Association of Physicians of India"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.jceh.2013.02.242","article-title":"Noradrenaline is equally effective as terlipressin in reversal of type 1 hepatorenal syndrome: a randomized prospective study","volume":"3","author":"Indrabi","year":"2013","journal-title":"Journal of Clinical and Experimental Hepatology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response","volume":"103","author":"Sharma","year":"2008","journal-title":"American journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0012|cit12","first-page":"449A","article-title":"Noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome: a randomized controlled trial","volume":"44","author":"Sharma","year":"2006","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","article-title":"Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study","volume":"56","author":"Singh","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jceh.2015.08.003","article-title":"Randomized controlled trial comparing the efficacy of terlipressin and albumin with a combination of concurrent dopamine, furosemide, and albumin in hepatorenal syndrome","volume":"5","author":"Srivastava","year":"2015","journal-title":"Journal of Clinical and Experimental Hepatology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0015|cit15","first-page":"39","article-title":"A randomized, placebo-controlled, double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design","volume":"4","author":"Boyer","year":"2012","journal-title":"Open Access Journal of Clinical Trials"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0017|cit17","first-page":"378A","article-title":"Terlipressin given as continuous intravenous infusion is the more suitable schedule for the treatment of type 1 hepatorenal syndrome (HRS) in patients with cirrhosis: results of a controlled clinical study","volume":"48","author":"Angeli","year":"2008","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.28396","article-title":"Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study","volume":"63","author":"Cavallin","year":"2015","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"165A","DOI":"10.1016\/0270-9139(95)94386-2","article-title":"Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross-over study","volume":"22","author":"Hadengue","year":"1995","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0168-8278(98)80151-7","article-title":"Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross-over study","volume":"29","author":"Hadengue","year":"1998","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0022|cit21","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0168-8278(07)61680-8","article-title":"Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome","volume":"46","author":"Martin-Llahi","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0021|cit22","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study","volume":"134","author":"Mart\u00edn-Llah\u00ed","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s10620-007-9919-9","article-title":"Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome","volume":"53","author":"Neri","year":"2008","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0024|cit24","first-page":"21","article-title":"Response to Terlipressin and albumin is associated with improved outcome in patients with cirrhosis and hepatorenal syndrome","volume":"140","author":"Nguyen-Tat","year":"2015","journal-title":"Deutsche Medizinische Wochenschrift"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0025|cit25","first-page":"34","article-title":"Low doses of terlipressin and albumin in the type I hepatorenal syndrome","volume":"2","author":"Pulvirenti","year":"2008","journal-title":"Italian Journal of Medicine"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0026|cit26","first-page":"694A","article-title":"A prospective, randomized, double blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS)","volume":"44","author":"Sanyal","year":"2006","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0028|cit28","first-page":"1071A","article-title":"Effect of terlipressin on mean arterial pressure (MAP) and its relation to serum creatinine concentration in type 1 hepatorenal syndrome (HRS): analysis of data from the pivotal phase 3 trial","volume":"48","author":"Sanyal","year":"2008","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0029|cit29","first-page":"565A","article-title":"Prognostic factors for hepatorenal syndrome (HRS) in patients with type 1 HRS enrolled in a randomized double-blind, placebo-controlled trial","volume":"46","author":"Sanyal","year":"2007","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0030|cit30","first-page":"1946","article-title":"Efficacy of terlipressin and albumin in the treatment of hepatorenal syndrome","volume":"12","author":"Silawat","year":"2011","journal-title":"World Applied Sciences Journal"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial","volume":"18","author":"Solanki","year":"2003","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0032|cit32","first-page":"764","article-title":"Noradrenalin versus the combination of midodrine and octreotide in patients with hepatorenal syndrome: randomized clinical trial","volume":"3","author":"Tavakkoli","year":"2012","journal-title":"International Journal of Preventive Medicine"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0033|cit33","first-page":"349","article-title":"A comparative study of high-or low-dose terlipressin therapy in patients with cirrhosis and type 1 hepatorenal syndrome","volume":"22","author":"Wan","year":"2014","journal-title":"Chinese Journal of Hepatology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0034|cit34","first-page":"123","article-title":"Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome","volume":"7","author":"Yang","year":"2001","journal-title":"Journal of Internal Intensive Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011532.pub2-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005162.pub4","article-title":"Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome","author":"Allegretti","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","article-title":"Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide","volume":"29","author":"Angeli","year":"1999","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/gutjnl-2014-308874","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites","volume":"64","author":"Angeli","year":"2015","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hep.510230122","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club","volume":"23","author":"Arroyo","year":"1996","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1665-2681(19)32154-4","article-title":"Hepatorenal syndrome","volume":"2","author":"Cardenas","year":"2003","journal-title":"Annals of Hepatology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/jhep.2002.34343","article-title":"Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study","volume":"36","author":"Duvoux","year":"2002","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2010.05.004","article-title":"EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis","volume":"53","author":"European Association for the Study of the Liver","year":"2010","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/039139880903200303","article-title":"Terlipressin for hepatorenal syndrome: a meta-analysis of randomized trials","volume":"32","author":"Fabrizi","year":"2009","journal-title":"International Journal of Artificial Organs"},{"issue":"2","key":"10.1002\/14651858.CD011532.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S2468-1253(16)30157-1","article-title":"Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis","volume":"2","author":"Facciorusso","year":"2017","journal-title":"Lancet Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jhep.2011.10.016","article-title":"Renal failure and cirrhosis: a systematic review of mortality and prognosis","volume":"56","author":"Fede","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD011532.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/apt.13912","article-title":"Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1","volume":"45","author":"Gifford","year":"2017","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","article-title":"Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis","volume":"105","author":"Gines","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(03)14903-3","article-title":"Hepatorenal syndrome","volume":"362","author":"Gines","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0048|cit48","unstructured":"Gluud C Nikolova D Klingenberg SL Cochrane Hepato-Biliary Group About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2017, Issue 6. Art. No.: LIVER"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0049|cit49","unstructured":"Brozek J Oxman A Sch\u00fcnemann H GRADEpro 2008"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1740774508091600","article-title":"Imputation methods for missing outcome data in meta-analysis of clinical trials","volume":"5","author":"Higgins","year":"2008","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0052|cit52","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0053|cit53","volume-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/jgh.12709","article-title":"Acute kidney injury and hepatorenal syndrome in cirrhosis","volume":"30","author":"Israelsen","year":"2015","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s12325-008-0118-7","article-title":"Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome","volume":"25","author":"Krag","year":"2008","journal-title":"Advances in Therapy"},{"issue":"3","key":"10.1002\/14651858.CD011532.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MEG.0000000000000537","article-title":"Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation","volume":"28","author":"Mattos","year":"March 2016","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Critical Care"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2036.2004.02112.x","article-title":"Review article: pathogenesis and pathophysiology of hepatorenal syndrome - is there scope for prevention?","volume":"20","author":"Moller","year":"2004","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"e107466","DOI":"10.1371\/journal.pone.0107466","article-title":"Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis","volume":"9","author":"Nassar","year":"2014","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000044879","article-title":"Circadian rhythm of arginine vasopressin in hepatorenal syndrome","volume":"78","author":"Pasqualetti","year":"1998","journal-title":"Nephron"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0061|cit61","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"4","key":"10.1002\/14651858.CD011532.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.20766","article-title":"Circulatory function and hepatorenal syndrome in cirrhosis","volume":"42","author":"Ruiz-del-Arbol","year":"2005","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"4","key":"10.1002\/14651858.CD011532.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/hep.26359","article-title":"Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012","volume":"57","author":"Runyon","year":"2013","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa067373","article-title":"Vasopressin versus norepinephrine infusion in patients with septic shock","volume":"358","author":"Russell","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0066|cit66","first-page":"1310","article-title":"Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis","volume":"56","author":"Salerno","year":"2007","journal-title":"Gut"},{"issue":"67","key":"10.1002\/14651858.CD011532.pub2-BIB0067|cit67","first-page":"1","article-title":"Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis","volume":"15","author":"Salerno","year":"2015","journal-title":"BMC Gastroenterology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"428","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011532.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM199908053410603","article-title":"Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"341","author":"Sort","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0070|cit70","unstructured":"StataCorp LP Stata 2014"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0071|cit71","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User manual for Trial Sequential Analysis (TSA) ctu.dk\/tsa\/files\/tsa_manual.pdf"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0072|cit72","unstructured":"Copenhagen Trial Unit TSA - Trial Sequential Analysis 2011"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD011532.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial Sequential Analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev","year":"2017","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD011532.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/hep.23286","article-title":"Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome","volume":"51","author":"Gluud","year":"2010","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"9","key":"10.1002\/14651858.CD011532.pub2-BIB0077|cit77","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005162.pub3","article-title":"Terlipressin for hepatorenal syndrome","author":"Gluud","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011532.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T19:03:19Z","timestamp":1628708599000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011532.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,27]]},"references-count":77,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011532.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,27]]}}}